Latest Options News

Jindalee Lithium has successfully raised $8 million through a private placement, complemented by a $1 million Share Purchase Plan, to advance its McDermitt Lithium Project and a strategic US SPAC transaction.

European Lithium Limited has launched a replacement options offer for holders of 205 million expiring options, with directors committing to fully participate and underwrite the offer pending shareholder approval at the upcoming AGM.

Aurora Energy Metals reports strong metallurgical results and progress toward Eagle Energy Metals’ Nasdaq listing, advancing the Aurora Uranium Project’s development.

BCAL Diagnostics has launched a $10 million convertible note facility, with $5 million already committed, to strengthen its capital position and accelerate commercialisation of its cancer detection technologies.

Singular Health Group has advanced its US expansion through the deployment of 3DICOM™ licenses under a key contract with Provider Network Solutions, alongside appointing a new US commercial chief to drive growth.

Chilwa Minerals has confirmed a significant carbonatite-hosted rare earth element discovery at its Mpyupyu target in Malawi, with initial drilling revealing elevated total rare earth oxide grades. This breakthrough supports the company’s strategy to develop a major rare earth system within its tenements.

Australian Strategic Materials secures A$50.8 million via share placement to fund Korean plant expansion and advance US metals project, while navigating complex supply chain and funding risks.

Raiz Invest has hit a record $2 billion in funds under management, driven by strong customer growth and innovative product launches. The fintech’s latest quarter also saw strategic partnerships expand its market reach.

Asian Battery Metals PLC has successfully raised $6 million through an oversubscribed equity placement, positioning the company to advance exploration and acquisition efforts across its Mongolian battery metals projects.

AdAlta Limited has raised up to A$1.1 million through a private placement, boosting its war chest to advance innovative cellular immunotherapy projects targeting solid cancers.

Neuren Pharmaceuticals has secured FDA Fast Track designation for its drug NNZ-2591 targeting Phelan-McDermid syndrome, accelerating its path through clinical development. This milestone underscores the urgent need for treatments in rare neurodevelopmental disorders.

Radiopharm Theranostics has completed a A$35 million institutional placement and launched a A$5 million Share Purchase Plan, both at $0.03 per share, to fund drug manufacturing and clinical trials through 2027.